Roche has entered into a collaboration with Warp Drive Bio aiming to discover and develop multiple classes of antibiotics with novel structures and mechanisms of action.
Under the alliance, Warp Drive will use its proprietary Genome Mining Platform to advance multiple novel classes of antibiotics with activity against clinically important, drug-resistant, Gram-negative pathogens.
The company said it is identifying and evaluating over one hundred novel classes of potential antibiotics that were previously undiscovered and thus never analysed for their impact on human health.
“We are committed to bringing urgently needed novel antibiotic medicines to patients, and we are delighted to be collaborating with Roche in that goal,” said Laurence Reid, Warp Drive Bio’s chief executive.
“Antimicrobial resistance is an extraordinary threat to global human health, and Warp Drive’s unique platform allows us to access a vast reservoir of uncharacterised natural products from which to identify novel antibiotics.”
The deal gives Roche an option for an exclusive worldwide license to develop and commercialise certain antibiotic classes that emerge from the collaboration, while Warp Drive will retain worldwide rights to all other novel antibiotic classes.
Warp Drive will receive up to $87 million in upfront payment, option fees, and milestone payments for preclinical events, and up to $300 million in payments related to specific clinical, regulatory and sales milestones on products licensed to Roche. In addition, the firm also stands to receive tiered royalties for products licensed to Roche.
By Selina McKee
Source: Pharma Times
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
